Zusammenfassung
More than 10% of the patients with colorectal cancer present with peritoneal carcinomatosis at initial surgery. The treatment of choice for these patients is systemic chemotherapy. With the introduction of cytoreductive surgery followed by (hyperthermic) intraperitoneal chemotherapy, there is a novel therapeutic option for patients with isolated peritoneal carcinomatosis. Numerous studies showed ...
Zusammenfassung
More than 10% of the patients with colorectal cancer present with peritoneal carcinomatosis at initial surgery. The treatment of choice for these patients is systemic chemotherapy. With the introduction of cytoreductive surgery followed by (hyperthermic) intraperitoneal chemotherapy, there is a novel therapeutic option for patients with isolated peritoneal carcinomatosis. Numerous studies showed an improvement of survival rates in comparison to treatment with systemic chemotherapy only. In specialized centers, morbidity and mortality rates seem to be acceptable. Preoperative patient selection and accurate diagnostics play a pivotal role for postoperative patient outcome. The clinical performance status and co-morbidities of the patients have to be taken into account before surgery is performed. Under these conditions cytoreductive surgery in combination with intraperitoneal chemotherapy seems to be an efficient and promising treatment strategy for patients with peritoneal carcinomatosis. However, its value in the treatment of colorectal cancer patients has to be evaluated in future, prospective, randomized studies.
Altmetric